Clinical Trials

The McDevitt laboratory is now involved in 6 clinical trials involving the programmable bio-nano-chip for major diseases in the areas of cardiac heart disease, oral cancer, ovarian cancer, prostate cancer and drugs of abuse. These translational activities are unique and place this approach in a position to make transformative changes to the US and global healthcare. John T. McDevitt has recently established the "Texas Cancer Diagnostics Pipeline" and serves at the Director for the newly formed "Early Disease Detection Gulf Coast Consortium Cluster" thereby creating a network of over 100 clinical researchers devoted to next generation of affordable diagnostics. Collectively these activities are helping to move swiftly these medical microdevices from the bench to the bedside. Read more about these bench to the bedside translational activities.